Company Overview and News
The largest three positions are Alliance Data Systems, Charles Schwab, and Alphabet, and they add up to ~42% of the portfolio.
According to the EIA’s (U.S. Energy Information Administration) latest Drilling Productivity Report, US crude oil production from the seven key shale plays (Anadarko, Appalachia, Bakken, Eagle Ford, Haynesville, Niobrara, and Permian) will rise 144 Mboepd (thousand barrels of oil equivalent per day) in June to ~7.2 MMboepd (million barrels of oil equivalent per day) compared to May.
Positive free cash flow projections for Antero Midstream Partners create guidance for heavy upside in dividend payouts.
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio.
The U.S. Energy Department's weekly inventory release showed a smaller-than-expected increase in natural gas supplies. The bullish report boosted the fuel’s price, which added around 3.5% for the week.
Chesapeake Energy stock’s (CHK) implied volatility is ~51.8%. In comparison, Noble Energy (NBL) and Antero Resources (AR) have lower implied volatility, of ~30.5% and ~31.5%, respectively. Meanwhile, the Energy Select Sector SPDR ETF (XLE) has implied volatility of ~19.3%.
The natural gas–weighted stocks that could be the most sensitive to US crude oil’s moves based on the correlations in the past five trading sessions with US crude oil June futures include:
In the week ending April 27, natural gas inventories rose by 62 Bcf (billion cubic feet) to 1,343 Bcf—based on the EIA’s (U.S. Energy Information Administration) data announced on May 3. The rise was 15 Bcf more than the market’s expectation. On May 3, natural gas June futures fell 1% due to bearish inventory data.
May 7 (Reuters) - Environmental regulators in West Virginia said Energy Transfer Partners LP could restart work on its $4.2 billion Rover natural gas pipeline after ordering the company to stop some work in the state due to permit violations:
WildHorse Resource Development is up 40% over the past 4 weeks and has soared to new all-time highs.
May 3 (Reuters) - The Pennsylvania Public Utility Commission (PUC) said on Thursday that all five commissioners voted to allow Energy Transfer Partners LP to restart its Sunoco Mariner East 1 natural gas liquids (NGL) pipeline.
(Reuters) - The Pennsylvania Public Utility Commission (PUC) said on Thursday that all five commissioners voted to allow Energy Transfer Partners LP to restart its Sunoco Mariner East 1 natural gas liquids (NGL) pipeline.
On May 1, natural gas June 2018 futures rose 1.4% and settled at $2.80 per MMBtu (million British thermal units). The rise limited natural gas’s trailing week decline to 0.4%.
May 1 (Reuters) - Energy Transfer Partners LP (ETP) said on Monday it filed with Pennsylvania utility regulators on Friday to restart its Sunoco Mariner East 1 natural gas liquids pipeline and hopes the line will return to service this week.
(Reuters) - Energy Transfer Partners LP (ETP) said on Monday it filed with Pennsylvania utility regulators on Friday to restart its Sunoco Mariner East 1 natural gas liquids pipeline and hopes the line will return to service this week.
14m - Asif
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
as of ET